抄録
Purpose: Chemoradiation therapy for head and neck cancer may make some normal tissue toxicity and affecting quality of life of patients during and after treatment. Method: We prospectively studied 40 patients with advanced head and neck cancers who were received concurrent chemoradiotherapy. Patients were divided into two groups consecutively: BRK group received concurrent chemoradiotherapy with 1000 mg of EF-2001 three times per day during whole treatment schedule of concurrent chemoradiation therapy. Results: 33 patients were evaluated. There was no statistical difference comparing BRK group against NBRK group at first treatment week. The most remarkable change during the treatment is QOL score of the gastrointestinal symptom and the appetite in BRK group was reported. Conclusion: The use of EF-2001 as nutritional supplement may be proposed as a means of improving the worsening in quality of life for head and neck cancer patients during chemoradiation treatment. [J Radiat Res 44:451 (2003)]
